Dr Alastair Greystoke is an Honorary Medical Oncologist at Newcastle’s Northern Centre for Cancer Care specialising in lung cancer, frailty in cancer, personalised medicine and drug development. He is also a Lecturer in Medical Oncology at Newcastle University.
Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after eight years spent at the University of Manchester’s Christie NHS Trust.
He is involved in the running of the Sir Bobby Robson Early Clinical Trials Centre at the Freeman Hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with thoracic (lung) malignancies.
In addition, he is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in NSCLC), Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub and he leads the Pharmacodynamic Biomarker team at the Centre for Cancer Research, Newcastle University.
